AMPH logo

AMPHASTAR PHARMACEUTICALS IN

AMPHNASDAQ
πŸ† #2347 by market capEarnings Nov 4US Equity
$26.68β–Ό $0.69 (βˆ’2.59%)
πŸŒ™ After hours$26.50β–Ό 0.67%Regular close Β· extended-hours price shown
πŸ””
Track AMPH
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 2.6%
7dβ–² 9.6%
14dβ–² 12.7%
30dβ–² 21.2%
ytdβ–Ό 0.4%
1yβ–Ό 1.0%
🏦Market Cap
$1.18B
Small Cap
πŸ“ˆRevenue Growth (YoY)
-1.6%
Declining
πŸ“ŠGross Margin
47.7%
Healthy
πŸ’΅FCF Margin
20.9%
Strong
βš–οΈP/S Ratio
1.7x
Cheap
Otter Score
72
Fair

Trading Snapshot

Day Range
$26.50 – $27.18
52-Week Range
$16.65 – $29.52
Volume
$2.93B
Avg Volume
$2.62B
Shares Outstanding
44.1M
Next Earnings
Dec 14, 2026

Fundamentals Snapshot

Annual Revenue
$720M
Last Q Revenue
$184M
P/E Ratio
15.7
P/S Ratio
1.7x
EPS (TTM)
$1.80
Dividend Yield
0.00%
Dilution (1yr)
βˆ’9.4%

Why Investors Own AMPH

  • βœ“High-growth profile β€” revenue up +25.4% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 29% gross margin and 7% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

AMPH logo

AMPHASTAR PHARMACEUTICALS IN

AMPH
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$720Mβ–Ό βˆ’1.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
49.5%β–Ό βˆ’3.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$140Mβ–Ό βˆ’31.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$121Mβ–Ό βˆ’29.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
47.2Mβ–Ό βˆ’9.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$486Mβ–² +$13M YoY
StockOtter Β· stockotter.space

About AMPHASTAR PHARMACEUTICALS IN

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
72/100

Analyst Ratings

β“˜
Consensus
Hold
12 analysts
Strong Buy0
Buy0
Hold8
Sell2
Strong Sell2
Ratings as of Sep 2026

Latest News & Updates

Defense WorldΒ·9d ago

Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Sells $239,400.00 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) EVP Rong Zhou sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an a

PRNewsWireΒ·28d ago

Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference

RANCHO CUCAMONGA, Calif., Sept. 1, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc.Β (NASDAQ: AMPH)Β announced today thatΒ Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be pre

Zacks Investment ResearchΒ·Aug 27

3 Generic Drug Stocks to Watch Amid Improving Industry Trends

The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.

Zacks Investment ResearchΒ·Aug 14

New Strong Sell Stocks for August 14th

AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.

Seeking AlphaΒ·Aug 7

Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript

Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript

Zacks Investment ResearchΒ·Aug 6

Compared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the y